Cover Image
市場調查報告書

創傷後壓力症候群(PTSD):開發平台分析

Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 213134
出版日期 內容資訊 英文 137 Pages
訂單完成後即時交付
價格
Back to Top
創傷後壓力症候群(PTSD):開發平台分析 Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2016
出版日期: 2016年07月27日 內容資訊: 英文 137 Pages
簡介

創傷後壓力症候群(PTSD)是指遭遇或目擊可怕的事情後引起的精神衛生狀態。症狀不僅有不斷閃回事件畫面、惡夢及嚴重不安,還包括了無法控制自己對創傷回億的思考。治療有給予抗憂鬱藥,抗焦慮·意識療法等。

本報告提供全球治療創傷後壓力症候群(PTSD)用之開發中產品的開發情形相關分析,提供您產品開發·上市的最新趨勢,臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

創傷後壓力症候群(PTSD)概要

治療藥的開發

  • 創傷後壓力症候群(PTSD)開發中產品:概要
  • 創傷後壓力症候群(PTSD)開發中產品:比較分析

創傷後壓力症候群(PTSD):各企業正在開發的治療藥

創傷後壓力症候群(PTSD):大學/研究機關研究中的治療藥

創傷後壓力症候群(PTSD):開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 未確認階段的產品

創傷後壓力症候群(PTSD):開發中的產品的一覽(各企業)

創傷後壓力症候群(PTSD):研究中的產品的一覽(大學/研究機關別)

創傷後壓力症候群(PTSD)的開發企業

  • Addex Therapeutics Ltd
  • Amorsa Therapeutics Inc.
  • Azevan Pharmaceuticals, Inc.
  • 分析的背景 Pharmaceutical Partners, Inc.
  • Eli Lilly and Company
  • HolsboerMaschmeyer NeuroChemie GmbH
  • Humanetics Corporation
  • Intra-Cellular Therapies, Inc.
  • INVENT Pharmaceuticals, Inc.
  • Marinus Pharmaceuticals, Inc.
  • Neuralstem, Inc.
  • NeuroNascent, Inc.
  • Omeros Corporation
  • 大塚集團
  • Polleo Pharma Limited
  • Synchroneuron Inc.
  • Tonix Pharmaceuticals Holding Corp.
  • Turing Pharmaceuticals AG
  • Vanda Pharmaceuticals Inc.

創傷後壓力症候群(PTSD):治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • acamprosate calcium SR
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • ADX-71743
  • AM-3506
  • brexpiprazole
  • CPP-115
  • Drug for Post-Traumatic Stress Disorders
  • Drugs to Inhibit FAAH for CNS Disorders
  • Drugs to Modulate NPSR for Anxiety Disorder
  • ganaxolone
  • HL-9001
  • IC-87201
  • iloperidone
  • INV-170
  • ITI-007
  • ketamine hydrochloride
  • NNI-351
  • NSI-189
  • Rycal
  • S-107
  • Small Molecule to Target GPR151 for CNS Diseases
  • Small Molecule to Target GPR83 for CNS and Immunological Disorders
  • Small Molecules for Post-Traumatic Stress Disorder
  • Small Molecules for Post-Traumatic Stress Disorder
  • Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders
  • Small Molecules to Antagonize mGluR7 For Central Nervous System Disorders
  • Small Molecules to Antagonize mGluR7 for Post-Traumatic Stress Disorders and Acute Stress Disorder
  • Small Molecules to Antagonize TLR-4 for CNS Disorders
  • SRX-246
  • TNX-102
  • Vaccine for CNS Disorders
  • vigabatrin
  • ZL-006

創傷後壓力症候群(PTSD):開發中產品的最新趨勢

創傷後壓力症候群(PTSD):開發暫停的產品

創傷後壓力症候群(PTSD):開發中止的產品

創傷後壓力症候群(PTSD)相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8308IDB

Summary

Global Markets Direct's, 'Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H2 2016', provides an overview of the Post-Traumatic Stress Disorder (PTSD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD)
  • The report reviews pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Post-Traumatic Stress Disorder (PTSD) therapeutics and enlists all their major and minor projects
  • The report assesses Post-Traumatic Stress Disorder (PTSD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Post-Traumatic Stress Disorder (PTSD) Overview
  • Therapeutics Development
    • Pipeline Products for Post-Traumatic Stress Disorder (PTSD) - Overview
    • Pipeline Products for Post-Traumatic Stress Disorder (PTSD) - Comparative Analysis
  • Post-Traumatic Stress Disorder (PTSD) - Therapeutics under Development by Companies
  • Post-Traumatic Stress Disorder (PTSD) - Therapeutics under Investigation by Universities/Institutes
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Post-Traumatic Stress Disorder (PTSD) - Products under Development by Companies
  • Post-Traumatic Stress Disorder (PTSD) - Products under Investigation by Universities/Institutes
  • Post-Traumatic Stress Disorder (PTSD) - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Amorsa Therapeutics Inc.
    • Azevan Pharmaceuticals, Inc.
    • Bionomics Limited
    • Catalyst Pharmaceuticals, Inc.
    • Eli Lilly and Company
    • Humanetics Corporation
    • Intra-Cellular Therapies, Inc.
    • INVENT Pharmaceuticals, Inc.
    • Marinus Pharmaceuticals, Inc.
    • Neuralstem, Inc.
    • NeuroNascent, Inc.
    • Omeros Corporation
    • Otsuka Holdings Co., Ltd.
    • Polleo Pharma Limited
    • Pragma Therapeutics
    • Synchroneuron Inc.
    • Tonix Pharmaceuticals Holding Corp.
    • TRImaran Pharma, Inc.
    • Turing Pharmaceuticals AG
  • Post-Traumatic Stress Disorder (PTSD) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • acamprosate calcium SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADX-71743 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AM-3506 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BNC-210 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • brexpiprazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CPP-115 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • D-473 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ganaxolone - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HL-9001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IC-87201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INV-107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INV-170 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ITI-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KDAC-0001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ketamine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • modafinil - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NNI-351 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NSI-189 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PGT-117 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Rycal - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • S-107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Target GPR151 for CNS Diseases - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Target GPR83 for CNS and Immunological Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Post-Traumatic Stress Disorder - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize mGluR7 For Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Target NMDA Receptor for Post-Traumatic Stress Disorder - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SRX-246 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Antagonize EPHA4 for Post-Traumatic Stress Disorder - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TNX-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • URB-694 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ZL-006 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Post-Traumatic Stress Disorder (PTSD) - Dormant Projects
  • Post-Traumatic Stress Disorder (PTSD) - Discontinued Products
  • Post-Traumatic Stress Disorder (PTSD) - Product Development Milestones
    • Featured News & Press Releases
      • Jun 30, 2016: Bionomics To Trial Drug Against Post-Traumatic Stress Disorder
      • Jun 13, 2016: Addex mGluR7 Program Demonstrate Potential in Preclinical Models of Neurodegenerative and Psychiatric Diseases
      • Jun 03, 2016: Tonix Pharmaceuticals to Present at the 2016 BIO International Convention
      • May 31, 2016: Tonix Pharmaceuticals Presents Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder at the American Society of Clinical Psychopharmacology 2016 Annual Meeting
      • May 26, 2016: Tonix Pharmaceuticals to Present Positive Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder at the ASCP 2016 Annual Meeting
      • May 19, 2016: Tonix Pharmaceuticals Reports Positive Topline Results from Phase 2 AtEase Study of TNX-102 SL in Post-Traumatic Stress Disorder (PTSD)
      • Mar 09, 2016: Tonix Pharmaceuticals Presents Pharmacokinetic Data on TNX-102 SL as a Potential Treatment for the Management of Fibromyalgia and Treatment of Post-Traumatic Stress Disorder at the ASCPT 2016 Annual Meeting
      • Dec 23, 2015: Tonix Pharmaceuticals Completes Enrollment in Phase 2 Clinical Trial of TNX-102 SL in Post-Traumatic Stress Disorder
      • Dec 08, 2015: Post Traumatic Stress Disorder Identified as Major New Market Opportunity for BNC210
      • Nov 23, 2015: The SEVEN4PTSD consortium led by PRAGMA Therapeutics awarded 2015 French ANR grant to further advance its mGlu7 program for Post-Traumatic Stress Disorder
      • Oct 29, 2015: Marinus Announces Clinical Development Plans for Ganaxolone Intravenous Formulation
      • Aug 18, 2015: Tonix Pharmaceuticals Presents on the Development of TNX-102 SL for Post-Traumatic Stress Disorder (PTSD) at the 2015 Military Health System Research Symposium
      • May 26, 2015: Tonix Pharmaceuticals Announces Acceptance of Two Abstracts for Presentation at EULAR
      • May 15, 2015: Tonix Pharmaceuticals Presents Data at the Annual Meeting of the Society for Biological Psychiatry
      • Jan 15, 2015: Tonix Pharmaceuticals Commences Phase 2 Trial of TNX-102 SL in Post-Traumatic Stress Disorder
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H2 2016
  • Number of Products under Development for Post-Traumatic Stress Disorder (PTSD) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Amorsa Therapeutics Inc., H2 2016
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Azevan Pharmaceuticals, Inc., H2 2016
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Bionomics Limited, H2 2016
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Catalyst Pharmaceuticals, Inc., H2 2016
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Eli Lilly and Company, H2 2016
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Humanetics Corporation, H2 2016
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Intra-Cellular Therapies, Inc., H2 2016
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Marinus Pharmaceuticals, Inc., H2 2016
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Neuralstem, Inc., H2 2016
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroNascent, Inc., H2 2016
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Omeros Corporation, H2 2016
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Otsuka Holdings Co., Ltd., H2 2016
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Polleo Pharma Limited, H2 2016
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Pragma Therapeutics, H2 2016
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Synchroneuron Inc., H2 2016
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Tonix Pharmaceuticals Holding Corp., H2 2016
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by TRImaran Pharma, Inc., H2 2016
  • Post-Traumatic Stress Disorder (PTSD) - Pipeline by Turing Pharmaceuticals AG , H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, H2 2016
  • Post-Traumatic Stress Disorder (PTSD) - Dormant Projects (Contd..1), H2 2016
  • Post-Traumatic Stress Disorder (PTSD) - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), H2 2016
  • Number of Products under Development for Post-Traumatic Stress Disorder (PTSD) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top